Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Zoeken op expertise, naam of affiliatie
Utility of adjuvant systemic therapy in melanoma
A. M.M. Eggermont
, A. Testori
, J. Marsden
, P. Hersey
, I. Quirt
, T. Petrella
, H. Gogas
, R. M. MacKie
, A. Hauschild
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
31
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Utility of adjuvant systemic therapy in melanoma'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Adjuvant Systemic Therapy
100%
Adjuvant Therapy
20%
AJCC Stage
20%
Central Europe
20%
Chemotherapy
20%
Clinical Trials
40%
Clinically Significant
20%
Control Arm
20%
Dermatologist
20%
Disease-free Survival
20%
Effective Compounds
20%
Europe
20%
High-dose Interferon
20%
Immunostimulant
20%
In(III)
20%
Interferon Therapy
20%
Interferon-α (IFN-α)
100%
Mediterranean Europe
20%
Melanoma
100%
Meta-analysis
20%
Northwest Europe
20%
Overall Survival
20%
Overall Survival Benefit
20%
Relapse-free Survival
20%
Response Predictors
20%
Stage II-III
20%
Stage IV Melanoma
20%
Treatment Duration
20%
Medicine and Dentistry
Adjuvant Therapy
100%
Arm
14%
Biological Marker
14%
Chemotherapy
14%
Clinical Trial
28%
Disease
28%
Disease Free Survival
14%
Drug Megadose
14%
Immunostimulating Agent
14%
Interferon
100%
Low Drug Dose
14%
Melanoma
100%
Meta-Analysis
14%
Overall Survival
28%
Recurrence Free Survival
14%
Treatment Duration
14%
Nursing and Health Professions
Adjuvant Therapy
100%
Biological Marker
14%
Dermatologist
14%
Disease
28%
Disease Free Survival
14%
Drug Megadose
14%
Immunostimulating Agent
14%
Interferon
100%
Low Drug Dose
14%
Melanoma
100%
Meta Analysis
14%
Overall Survival
28%
Recurrence Free Survival
14%
Treatment Duration
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
14%
Chemotherapy
14%
Clinical Trial
28%
Disease
28%
Disease Free Survival
14%
Immunostimulant
14%
Interferon
100%
Melanoma
100%
Overall Survival
28%
Recurrence Free Survival
14%
Immunology and Microbiology
Arm
14%
Disease Free Survival
14%
Drug Megadose
14%
Immunostimulant
14%
interferon
100%
Low Drug Dose
14%
Overall Survival
28%
Recurrence Free Survival
14%